Vanda Pharmaceuticals to Present Key Findings at ASCP Annual Meeting 2025

Vanda Pharmaceuticals at the ASCP Annual Meeting 2025

On May 27, 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation in the esteemed American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which will run from May 27 to May 30, 2025, in Scottsdale, Arizona. This significant gathering attracts leading minds in the field of clinical psychopharmacology, and Vanda's involvement showcases their commitment to advancing psychiatric treatment.

Presentation Details

During the event, Vanda will present key research findings pertaining to its new psychiatric drug, Bysanti™. This drug is currently undergoing intensive clinical evaluation as a novel atypical antipsychotic. The highlight of Vanda's presentation will be on May 27, featuring a poster titled "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets." This study aims to evaluate the comparative pharmacokinetics of two established medications in the field and will be presented by Dr. Sean R. Chadwick, an expert in clinical development.

Bysanti™ Overview

Bysanti™ represents a potential breakthrough in psychiatric pharmacotherapy. As a new chemical entity, it is designed to provide therapeutic benefits through its action on various neurotransmitter receptors within the brain, including the alpha-adrenergic receptor, serotonin receptors, and dopamine receptors. Should it receive approval, Bysanti™ is projected to be available for sale in the United States by 2026, significantly enhancing treatment options for patients struggling with severe mental health disorders. Moreover, Vanda's strategic planning involves exclusivity measures, including pending patent applications that may extend its market protection into the 2040s.

Vanda Pharmaceuticals: A Leader in Biopharmaceutical Innovation

As a prominent biopharmaceutical company, Vanda Pharmaceuticals is dedicated to developing and commercializing novel therapies that address significant unmet medical needs. Its focus extends on improving patients' lives through innovative drug design and rigorous research. Vanda’s commitment to advancing the field of psychopharmacology is evident in its ongoing research and collaborations within the scientific community.

For further insights about Vanda Pharmaceuticals Inc. and its pioneering work, visit their official website at www.vandapharma.com or connect on social media via X @vandapharma.

Conclusion

As the ASCP Annual Meeting approaches, anticipation builds around Vanda Pharmaceuticals’ contributions to the field of clinical psychopharmacology. The company’s initiatives are critical not only to the advancement of psychiatric medicine but also in enriching the lives of individuals affected by mental health disorders. With Bysanti™, Vanda stands at the forefront of innovation, promising hope for better therapeutic outcomes in the near future.